Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Case Series

Abstract

Table I. Dupilumab in paediatric patients with atopic dermatitis Study Cork et al. (2) Simpson et al. 1 Treister & Lio (3) Present stydy Number of patients 40 251 8 4 Dosage 2 or 4 mg/kg DUPI 300 mg q4w DUPI 200 mg/ 300 mg q2w DUPI 600 mg and 300 mg q2w Advances in dermatology and venereology

Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16‐week real‐life experience during the COVID ‐19 pandemic in Italy

“…In adolescents treated with dupilumab, the phase III randomized, placebo‐controlled, clinical trial (R668‐AD‐1526 LIBERTY AD ADOL, NCT03054428) 8 and the phase IIa and subsequent phase III open label extension (R668‐AD‐1412, NCT02407756; R668‐AD‐1434 LIBERTY AD PED‐OLE, NCT02612454) 9 showed significant improvement of AD signs and symptoms, with a good safety profile. To date, only few real‐world data are available on effectiveness and safety of dupilumab in adolescents 10 …”

“…To date, only few real-world data are available on effectiveness and safety of dupilumab in adolescents. 10…”

A single‐centre real‐life experience on effectiveness and safety of dupilumab in adolescents with severe atopic dermatitis in treatment with cyclosporine A

“…2 Gene polymorphisms that result in amino acid substitutions could affect the structure of the molecule and, therefore, become susceptible to autoantibody attack. 3 Clinically, this results in generalized or localized skin blistering, such as junctional epidermolysis bullosa 2 or epidermolysis bullosa simplex. 4 Until recently, the pathogenesis of hereditary and acquired autoimmune skin blistering diseases has been thought to be distinct.…”

“…Although large clinical trials in adolescents have demonstrated its safety and efficacy, 1,2 few real-life data are still available. 3 Studies carried out required a 4-week washout period for any systemic immunosuppressants prior to starting dupilumab. However, in clinical practice, this procedure is not often performed.…”

Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis

“…It is the first biologic treatment for AD approved by the food and drug administration (FDA) and European Medicines Agency (EMA) in 2017 based on clinical trials that have successfully proven its clinical safety and effectiveness [9][10][11]. Due to a strict patient selection policy in clinical trials, these data are not always reproducible in daily clinical practice, and real-world data may differ in effectiveness and safety [12]. Here, we present data of effectiveness and side effects of Dupilumab treatment in a real-life Austrian patient population.…”